October 23, 2013
This article was recently reported by the Washington Post.
The US Food and Drug Administration (FDA) this week planned to review two new drugs to treat hepatitis C. If approved, the drugs would offer a faster and more effective method to curing the blood-borne liver disease, which has become a major health concern for millions of baby boomers. Hepatitis C was responsible for approximately 15,000 US deaths this year.
Johnson & Johnson (J&J) and Gilead Sciences submitted their latest experimental drugs that had the potential to treat the 3-4 million infected Americans. Health officials encouraged baby boomers to get tested because the virus could lie dormant for decades before causing health problems or symptoms. Health officials believed baby boomers contracted the disease through sex or sharing needles in their youth, or by having blood transfusions before 1992, which was when medical facilities began testing all donated blood for hepatitis.
Hepatitis C treatments throughout the past 20 years have involved a difficult one-year regimen of both pills and injections that have unpleasant side effects and only cure approximately half of the patients. Two drugs, introduced in 2011 and taken concurrently with the previous regimen, boosted the cure rate to up to 75 percent. J&J's drug, simeprevir, had a somewhat better cure rate than current treatments, as well as cut the treatment cycle in half, but side effects included rashes and sunburns. FDA planned to ask a panel of experts if the drug should carry a warning label. Gilead Sciences Inc.'s drug, sofosbuvir, had a 90-percent cure rate with only 12 weeks of therapy, which led analysts to believe this drug might become the therapy of choice to treat the disease.
10.22.2013; Associated Press
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|What's Hot in HIV Cure Research?|
|Extensively Drug-Resistant HIV Yields to a New Drug: Ibalizumab|
|A Review of Long-Acting HIV Treatment and Prevention|
|Top Menu Items From the Boiling Cauldron of HIV Clinical Research|
|This Week in HIV Research: Researchers Exonerate Long-Alleged 'Patient Zero,' and Triggering bNAb Production Shows Promise|